Halophosphate

Endpoint summary

Additional information

Ames test:

Halophosphate was tested according to current OECD/EC test guidelines in the Salmonella typhimurium reverse mutation assay with four histidine-requiring strains of Salmonella typhimurium (TA1535, TA1537, TA98 and TA100) and in the Escherichia coli reverse mutation assay with a tryptophan-requiring strain of Escherichia coli (WP2uvrA). The test was performed in two independent experiments in the presence and absence of two different concentrations of S9-mix. Halophosphate did not induce a significant dose-related increase in the number of revertant colonies in any of the five tester strains, both in the absence and presence of metabolic activation. No cytotoxicity was observed and slight precipitation was seen at limit concentrations. Based on the results of this study it is concluded that Halophosphate is not mutagenic in the Salmonella typhimurium reverse mutation assay and in the Escherichia coli reverse mutation assay with and without metabolic activation.

Chromosome aberration study

In a chromosome aberration study, cultured peripheral human lymphocytes were exposed to different concentrations of Halophosphate, in the presence and absence of S9-mix according to recent OECD and EC guidelines under GLP circumstances. Halophosphate was tested up to precipitating concentration (≥100 μg/ml). Halophosphate did not induce a statistically significant or biologically relevant increase in the number of cells with chromosome aberrations in the absence and presence of S9-mix. No effects of Halophosphate on the number of polyploid cells and cells with endoreduplicated chromosomes were observed both in the absence and presence of S9-mix. Therefore it can be concluded that Halophosphate does not disturb mitotic processes and cell cycle progression and does not induce numerical chromosome aberrations nor polyploidy.

Mouse lymphoma assay:

The mouse lymphoma assay was conducted according to OECD 476 guideline and GLP principles. The spontaneous mutation frequencies in the solvent-treated control cultures were between the minimum and maximum value of the historical control data range Positive control chemicals, methyl methane sulfonate and cyclophosphamide induced appropriate responses. In the absence of S9-mix, Halophospahte did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in an independent repeat experiment with modifications in the duration of treatment time. In the presence of S9-mix, Halophosphate did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in an independent repeat experiment with modifications in the concentration of the S9 for metabolic activation. Halophosphate was tested up to precipitating concentrations. Based on these data, it is concluded that Halophosphate is not mutagenic in the mouse lymphoma L5178Y test system under the experimental conditions described in the report.

Short description of key information:
A chromosome aberration study, an AMES test (Salmonella typhimurium reverse mutation assay and an Escherichia coli reverse mutation assay) and a mouse lymphoma assay were conducted with and without metabolic activation according to current OECD/EC guidelines under GLP circumstances. Based on the results of three different in vitro assays, it is concluded that Halophosphate is not mutagenic with or without metabolic activation.

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on the available data, Halophosphate does not have to be classified for mutagenicity according to CLP Regulation (EC) No 1272/2008.